Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Stocks · News reference
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Aligos Therapeutics, Inc. (ALGS)
Filed: 2026-09-15 AccNo: 0001193125-26-391880 Size: 141 KB Item 1.01: Entry into a Material Definitive Agreement
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.
Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $11 to $14.